The cardiac glycosides market in Italy is projected to decline steadily from 2024 to 2028, with sales expected to decrease from 3.4 million Euros in 2024 to 2.6 million Euros in 2028. This represents a consistent annual decrease in sales, indicating a downward trend in demand or price reductions. As of 2023, the market stood at a point not explicitly given, but the repetitive data suggests a focus on capturing a noticeable decline starting in 2024.
Year-on-year percentage variations highlight a decreasing trend, while the compound annual growth rate (CAGR) for the period emphasizes an average annual decline, underscoring the shrinking nature of the market.
Future trends to watch for include potential shifts towards alternative therapies, innovation in heart failure treatments, or broader healthcare policy changes impacting cardiac glycosides' applicability and usage.
